U.S. STOCKS ON THE MOVE-Nio Inc, Twilio Inc, Weber Inc
Drug developer GT Biopharma gains as cost cuts help narrow losses
Brief: GT Biopharma Reports First Quarter Fiscal 2022 Financial Results And Business Update
GT Biopharma Inc expected to post a loss of 31 cents a share - Earnings Preview
Brief: GT Biopharma Reports Fourth Quarter Net Loss Of $18.0 Mln
Brief: Gt Biopharma Appoints Manu Ohri As Chief Financial Officer
GT Biopharma set for best day in over 3 months on tumor therapy trial update
Brief: GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021
GT Biopharma Inc reports results for the quarter ended in September - Earnings Summary
Brief: GT Biopharma Posts Q3 Loss Per Share Of $0.17
U.S. STOCKS ON THE MOVE-Peloton, AMD, Coty, eHealth, 51job, Tesla
GT Biopharma falls on CEO, CFO departure
Brief: GT Biopharma Announces Executive Leadership Transition To Implement Next Phase Of Strategic Journey
Brief: GT Biopharma's Camelid TriKE® Nanobody Platform Highlighted At ESMO Congress 2021
Brief: GT Biopharma To Present Updated Positive Safety Data From GTB-3550 Monotherapy TriKE™ Trial At ESMO Congress 2021
Brief: GT Biopharma Advances GTB-3650 Into IND-Enabling Studies
Brief: GT Biopharma Announces Issuance Of Two New Patents Covering Trike Platform Technologies
GT Biopharma Inc reports results for the quarter ended in June - Earnings Summary
GT Biopharma Inc expected to post a loss of 28 cents a share - Earnings Preview